A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
Inclusion criteria:
Exclusion criteria:
Participate-In-This-Study1@its.jnj.com844-434-4210
Beverly Hills, California 90211, United States
Mineola, New York 11501, United States
Chaoyang District, 100020, China
Tijian, 300020, China
Athens, 124 62, Greece
Gunma, 371-0034, Japan
Wałbrzych, 58 309, Poland